PUB100 Clinical Outcomes of Non-Small Cell Lung Cancer (NSCLC) Patients with ALK Co-Mutations (EGFR or KRAS) Receiving Tyrosine Kinase Inhibitors (TKI)

Sabine Schmid; Oliver Gautschi; Sacha Rothschild; Laetitia Mauti; Michael Mark; Patrizia Froesch; Martin Früh

首页> 外文期刊>Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer >PUB100 Clinical Outcomes of Non-Small Cell Lung Cancer (NSCLC) Patients with ALK Co-Mutations (EGFR or KRAS) Receiving Tyrosine Kinase Inhibitors (TKI)

【24h】

PUB100 Clinical Outcomes of Non-Small Cell Lung Cancer (NSCLC) Patients with ALK Co-Mutations (EGFR or KRAS) Receiving Tyrosine Kinase Inhibitors (TKI)

机译：PUB100非小细胞肺癌（NSCLC）临床结果（NSCLC）患者ALK共突（EGFR或KRA）接受酪氨酸激酶抑制剂（TKI）

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer》 |2017年第1期|共1页
作者
Sabine Schmid; Oliver Gautschi; Sacha Rothschild; Laetitia Mauti; Michael Mark; Patrizia Froesch; Martin Früh;
展开▼
作者单位

Kantonsspital St. Gallen;

Medical Oncology Lucerne Cantonal Hospital;

Medical Oncology University Hospital Basel;

Kantonsspital Winterthur;

Kantonsspital Graubünden;

Eoc;

Kantonsspital St. Gallen;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. PUB100 Clinical Outcomes of Non-Small Cell Lung Cancer (NSCLC) Patients with ALK Co-Mutations (EGFR or KRAS) Receiving Tyrosine Kinase Inhibitors (TKI) [J] . Sabine Schmid, Oliver Gautschi, Sacha Rothschild, Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer . 2017,第1期

机译：PUB100非小细胞肺癌（NSCLC）临床结果（NSCLC）患者ALK共突（EGFR或KRA）接受酪氨酸激酶抑制剂（TKI）
2. PUB100 Clinical Outcomes of Non-Small Cell Lung Cancer (NSCLC) Patients with ALK Co-Mutations (EGFR or KRAS) Receiving Tyrosine Kinase Inhibitors (TKI) [J] . Sabine Schmid, Oliver Gautschi, Sacha Rothschild, Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer . 2017,第1期

机译：PUB100非小细胞肺癌（NSCLC）临床结果（NSCLC）患者ALK共突（EGFR或KRA）接受酪氨酸激酶抑制剂（TKI）
3. Clinical Outcome of ALK-Positive Non-Small Cell Lung Cancer (NSCLC) Patients with De Novo EGFR or KRAS Co-Mutations Receiving Tyrosine Kinase Inhibitors (TKIs)Sabine Schmid, Oliver Gautschi, Sacha Rothschild, ^z>Michael Mark, Patrizia Froesch, Dirk Klingbiel, Hermann Reichegger, Wolfram Jochum, Joachim Diebold, Martin Fruh, [J] . Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer . 2017,第4期

机译：ALK阳性非小细胞肺癌（NSCLC）患者的临床结果（NSCLC）患者DE Novo EGFR或KRAS共突变接受酪氨酸激酶抑制剂（TKIS）Sabine Schmid，Oliver Gautschi，Saha Rothschild，^ Z> Michael Mark，Patrizia Frosech， Dirk Klingbiel，Hermann Reichegger，Wolfram Jochum，Joachim Diebold，Martin Fruh，
4. Association between tumor heterogeneity and progression-free survival in non-small cell lung cancer patients with EGFR mutations undergoing tyrosine kinase inhibitors therapy [C] . Jiangdian Song, Di Dong, Yanqi Huang, Annual International Conference of the IEEE Engineering in Medicine and Biology Society . 2016

机译：接受酪氨酸激酶抑制剂治疗的EGFR突变非小细胞肺癌患者肿瘤异质性与无进展生存的关系
5. EGFR in Early Non-Small Cell Lung Cancer: Tyrosine Kinase Inhibition in a Neoadjuvant Trial. [D] . Lara-Guerra, Humberto. 2011

机译：早期非小细胞肺癌中的EGFR：新辅助试验中酪氨酸激酶抑制作用。
6. Impact of Weight Loss at Presentation on Survival in Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (EGFR-TKI) Sensitive Mutant Advanced Non-small Cell Lung Cancer (NSCLC) Treated with First-line EGFR-TKI [O] . Liping Lin, Juanjuan Zhao, Jiazhu Hu, 2018

机译：一线用EGFR-TKI治疗的体重减轻对表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKI）敏感突变晚期非小细胞肺癌（NSCLC）存活率的影响
7. PUB100 Clinical Outcomes of Non-Small Cell Lung Cancer (NSCLC) Patients with ALK Co-Mutations (EGFR or KRAS) Receiving Tyrosine Kinase Inhibitors (TKI) [O] . Sabine Schmid, Oliver Gautschi, Sacha Rothschild, 2017

机译：PUB100非小细胞肺癌（NSCLC）临床结果（NSCLC）患者ALK共突（EGFR或KRA）接受酪氨酸激酶抑制剂（TKI）

PUB100 Clinical Outcomes of Non-Small Cell Lung Cancer (NSCLC) Patients with ALK Co-Mutations (EGFR or KRAS) Receiving Tyrosine Kinase Inhibitors (TKI)

著录项

相似文献

相关主题

期刊订阅